Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives

被引：30

作者：

Patel, Jai N. ^{[1
]}

机构：

[1] Carolinas HealthCare Syst, Levine Canc Inst, Dept Canc Pharmacol, 1021 Morehead Med Dr,Rm 4336, Charlotte, NC 28204 USA

来源：

PHARMACOGENOMICS & PERSONALIZED MEDICINE | 2016年 / 9卷

关键词：

oncology; personalized; pharmacogenetics; germline; somatic; DNA; biomarker; CELL LUNG-CANCER; ELECTRONIC HEALTH RECORDS; MICROSATELLITE INSTABILITY; THIOPURINE METHYLTRANSFERASE; CLINICAL IMPLEMENTATION; GENETIC-POLYMORPHISM; 1ST-LINE TREATMENT; COLORECTAL-CANCER; RESISTANCE; GENOTYPE;

D O I：

10.2147/PGPM.S62918

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision medicine. Harnessing and understanding the genetic code of both the patient (germline) and the tumor (somatic) provides the opportunity for personalized dose and therapy selection for cancer patients. While germline DNA is useful in understanding the pharmacokinetic and pharmacodynamic disposition of a drug, somatic DNA is particularly useful in identifying drug targets and predicting drug response. Molecular profiling of somatic DNA has resulted in the current breadth of targeted therapies available, expanding the armamentarium to battle cancer. This review provides an update on cancer pharmacogenomics and genomics-based medicine, challenges in applying pharmacogenomics to the clinical setting, and patient perspectives on the use of pharmacogenomics to personalize cancer therapy.

引用

页码：65 / 77

页数：13

共 87 条

[81] From human genome to cancer genome: The first decade [J].

Wheeler, David A. ;

Wang, Linghua .

GENOME RESEARCH, 2013, 23 (07) :1054-1062

[82] Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia [J].

Yang, Jun J. ;

Landier, Wendy ;

Yang, Wenjian ;

Liu, Chengcheng ;

Hageman, Lindsey ;

Cheng, Cheng ;

Pei, Deqing ;

Chen, Yanjun ;

Crews, Kristine R. ;

Kornegay, Nancy ;

Wong, F. Lennie ;

Evans, William E. ;

Pui, Ching-Hon ;

Bhatia, Smita ;

Relling, Mary V. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) :1235-+

[83] SnapShot: EGFR signaling pathway [J].

Yarden, Yosef ;

Shilo, Ben-Zion .

CELL, 2007, 131 (05)

[84] The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP [J].

Yun, Cai-Hong ;

Mengwasser, Kristen E. ;

Toms, Angela V. ;

Woo, Michele S. ;

Greulich, Heidi ;

Wong, Kwok-Kin ;

Meyerson, Matthew ;

Eck, Michael J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (06) :2070-2075

[85] Public Perceptions of Pharmacogenetics [J].

Zhang, Steven C. ;

Bruce, Carleton ;

Hayden, Michael ;

Rieder, Michael J. .

PEDIATRICS, 2014, 133 (05) :E1258-E1267

[86] Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance [J].

Zhang, Wenyong W. ;

Cortes, Jorge E. ;

Yao, Hui ;

Zhang, Li ;

Reddy, Neelima G. ;

Jabbour, Elias ;

Kantarjian, Hagop M. ;

Jones, Dan .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3642-3649

[87] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J].

Zhou, Caicun ;

Wu, Yi-Long ;

Chen, Gongyan ;

Feng, Jifeng ;

Liu, Xiao-Qing ;

Wang, Changli ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Chengping ;

Hu, Chunhong ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu ;

Ma, Jun ;

Zhang, Li ;

You, Changxuan .

LANCET ONCOLOGY, 2011, 12 (08) :735-742

← 1 2 3 4 5 6 7 8 9 →